This report was first published by Endpoints News. To see the original version, click here
John Tsai, a former chief medical officer at Novartis and Amgen, will steer Daiichi Sankyo’s global R&D efforts starting April 1.
He’ll take over from Ken Takeshita, who is stepping down five years into the role. During that time, antibody-drug conjugates — for which Daiichi is known — blossomed in popularity and became one of the leading cancer treatment modalities for pharma dealmakers.
您已阅读16%（480字），剩余84%（2453字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。